Skip to content

Operating Income at other companies

ALN
Alnylam PharmaceuticalsALNY
$268.64M+1,386%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$13.3M+48.7%
Regenxbio logo
RegenxbioRGNX
-$83.36M-787%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$9.36M-512%
Opko Health logo
Opko HealthOPK
-$51.02M+24.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$71.37M+11.9%

Other financials

Income statement

See full
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's operating income?
Tectonic Therapeutics (TECX) reported operating income of -$27.3M in Q1 2026.
How has Tectonic Therapeutics's operating income changed year-over-year?
Tectonic Therapeutics's operating income decreased by 49.2% year-over-year, from -$18.3M to -$27.3M.
What is the long-term trend for Tectonic Therapeutics's operating income?
Over 4 years (2021 to 2025), Tectonic Therapeutics's operating income has grown at a -8.3% compound annual growth rate (CAGR), from -$118.84M to -$84.04M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.